Neurodegenerative Disease Market

Jun 2022| FMI1909A| Future Markets Insights

Report Highlights

Neurodegenerative disease or neurodegeneration refers to the progressive damage or wear and tear of the nerve cells. Neurodegenerative disease causes loss of abilities like decision making and eventually memory loss. Neurodegeneration is a broader term which comprises of different disease namely Parkinson’s disease, Huntington disease, Amyotrophic Lateral Sclerosis and Alzheimer’s disease.  These are the most commonly occurring diseases under the condition “Neurodegeneration”. Neurodegeneration can be caused due to genetic factor but the proportion is minimal. Major cause of neurodegeneration could be deposition of toxic protein substance in the brain or loss of functionality/improper functioning of mitochondria present in brain. Patients generally show mixture of symptoms for one or more neurodegenerative disease. Currently there is no cure for this condition however specific drugs are present in the market to minimize the symptoms (for example: donepezil and memantine for Alzheimer’s disease, L-dopa for Parkinson’s, riluzole for ALS).

Neurodegenerative Disease Market: Drivers & Restraints              

Neurodegenerative market is expected to dwell due to continuous advancement in medical technology both for the diagnosis and the treatment of neurological disorders have raised the demand of neurodegenerative drugs. Ageing population is increasing which in turn is leading to increase in the incidence of neurological disorders are some major factors driving the growth of neurodegenerative market. Growing awareness amongst the physicians is helping the market to dwell in developed countries. Developing countries especially Asia Pacific countries, where due to large population the market growth is expected to be significant in the upcoming years. Lack of complete curative treatment measures primarily because of the manifold nature of the disease could possibly hamper the market of neurodegenerative disease market at the global level.

Neurodegenerative Market: Segmentation

Neurodegenerative market is classified on the basis of Drug class, indications and geography.

Based on Drug class, the global Neurodegenerative disease market is segmented into the following:

  • NMDA
  • SSRIs
  • Dopamine Inhibitors

Based on Indications, the global Neurodegenerative disease market is segmented into the following:

  • Parkinson’s disease
  • Huntington disease
  • Amyotrophic Lateral Sclerosis
  • Alzheimer’s disease

Neurodegenerative Disease Market: Overview

Neurodegenerative disease market is expected to grow at a significant pace mainly due to increasing cases of neurological disorders. The market is expected to witness advancement in the upcoming years due to launch of new type of drugs. In the Alzheimer’s market, drugs like GABA receptor modulators, anti-amyloid protein agents and nicotinic and cholinergic receptor agonists are expected to influence the market growth however in the Parkinson’s disease market will be driven due to launch of drugs like dopamine receptor agonists and reuptake inhibitors, glutamate receptor modulators, and adrenergic and adenosine antagonists. New players are expected to enter the market in the forecast years due to patent protection loss for major players.

Neurodegenerative Market: Region-wise Outlook

Depending on geographic regions, global neurodegenerative disease market is segmented into seven key regions: North America, South America, Eastern Europe, Western Europe, Asia Pacific, Japan, and Middle East & Africa. Global market for neurodegenerative disease is expected to grow by a CAGR of around 5%. Asia Pacific is expected to witness the highest growth due to large population base over the forecast years.

Neurodegenerative Market: Key Players

Some of the key market players in global Neurodegenerative market are Novartis, Pfizer, Merck Serono, Biogen Idec, TEVA Pharmaceuticals Industries, UCB, Boehringer Ingelheim, Sanofi S.A., GlaxoSmithKline to name a few. Major players will face competition in the upcoming years due to patent protection loss.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.

The report covers exhaustive analysis on:

  • Market Segments
  • Market Dynamics
  • Market Size
  • Supply & Demand
  • Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Technology
  • Value Chain

Regional analysis includes

  • North America (U.S., Canada)
  • Latin America (Mexico. Brazil)
  • Western Europe (Germany, Italy, France, U.K, Spain, Rest of Western Europe)
  • Eastern Europe (Russia)
  • Asia Pacific (China, India, ASEAN, Australia & New Zealand)
  • Japan
  • Middle East and Africa (GCC, S. Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Synopsis

Report Metrics Details
Base year considered 2022
Forecast period considered 2022-2032
Units considered $ Million
Segments covered By Disease Indication, By Drug Class, By Route of Administration, By Distribution Channel, By Region, By Country
Industry covered Healthcare
Countries covered North America, Latin America, Asia Pacific, MEA, Europe
Companies studied
  • Novartis
  • UCB
  • Pfizer
  • Merck Serono
  • Biogen Idec
  • TEVA Pharmaceuticals Industries
  • Boehringer Ingelheim
  • Sanofi S.A.
  • GlaxoSmithKline

Report Highlights:

  • Detailed overview of parent market
  • Changing market dynamics in the industry
  • In-depth market segmentation
  • Historical, current and projected market size in terms of volume and value
  • Recent industry trends and developments
  • Competitive landscape
  • Strategies of key players and products offered
  • Potential and niche segments, geographical regions exhibiting promising growth
  • A neutral perspective on market performance
  • Must-have information for market players to sustain and enhance their market footprint.

NOTE - All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.

  • Table 1 : Global Market Value (US$ Mn) Forecast by Region, 2017-2032
  • Table 2 : Global Market Value (US$ Mn) Forecast by Disease Indication, 2017-2032
  • Table 3 : Global Market Value (US$ Mn) Forecast by Drug Class, 2017-2032
  • Table 4 : Global Market Value (US$ Mn) Forecast by Route of Administration, 2017-2032
  • Table 5 : Global Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
  • Table 6 : North America Market Value (US$ Mn) Forecast by Country, 2017-2032
  • Table 7 : North America Market Value (US$ Mn) Forecast by Disease Indication, 2017-2032
  • Table 8 : North America Market Value (US$ Mn) Forecast by Drug Class, 2017-2032
  • Table 9 : North America Market Value (US$ Mn) Forecast by Route of Administration, 2017-2032
  • Table 10 : North America Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
  • Table 11 : Latin America Market Value (US$ Mn) Forecast by Country, 2017-2032
  • Table 12 : Latin America Market Value (US$ Mn) Forecast by Disease Indication, 2017-2032
  • Table 13 : Latin America Market Value (US$ Mn) Forecast by Drug Class, 2017-2032
  • Table 14 : Latin America Market Value (US$ Mn) Forecast by Route of Administration, 2017-2032
  • Table 15 : Latin America Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
  • Table 16 : Europe Market Value (US$ Mn) Forecast by Country, 2017-2032
  • Table 17 : Europe Market Value (US$ Mn) Forecast by Disease Indication, 2017-2032
  • Table 18 : Europe Market Value (US$ Mn) Forecast by Drug Class, 2017-2032
  • Table 19 : Europe Market Value (US$ Mn) Forecast by Route of Administration, 2017-2032
  • Table 20 : Europe Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
  • Table 21 : East Asia Market Value (US$ Mn) Forecast by Country, 2017-2032
  • Table 22 : East Asia Market Value (US$ Mn) Forecast by Disease Indication, 2017-2032
  • Table 23 : East Asia Market Value (US$ Mn) Forecast by Drug Class, 2017-2032
  • Table 24 : East Asia Market Value (US$ Mn) Forecast by Route of Administration, 2017-2032
  • Table 25 : East Asia Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
  • Table 26 : South Asia & Pacific Market Value (US$ Mn) Forecast by Country, 2017-2032
  • Table 27 : South Asia & Pacific Market Value (US$ Mn) Forecast by Disease Indication, 2017-2032
  • Table 28 : South Asia & Pacific Market Value (US$ Mn) Forecast by Drug Class, 2017-2032
  • Table 29 : South Asia & Pacific Market Value (US$ Mn) Forecast by Route of Administration, 2017-2032
  • Table 30 : South Asia & Pacific Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
  • Table 31 : MEA Market Value (US$ Mn) Forecast by Country, 2017-2032
  • Table 32 : MEA Market Value (US$ Mn) Forecast by Disease Indication, 2017-2032
  • Table 33 : MEA Market Value (US$ Mn) Forecast by Drug Class, 2017-2032
  • Table 34 : MEA Market Value (US$ Mn) Forecast by Route of Administration, 2017-2032
  • Table 35 : MEA Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
  • Figure 1 : Global Market Value (US$ Mn) by Disease Indication, 2022-2032
  • Figure 2 : Global Market Value (US$ Mn) by Drug Class, 2022-2032
  • Figure 3 : Global Market Value (US$ Mn) by Route of Administration, 2022-2032
  • Figure 4 : Global Market Value (US$ Mn) by Distribution Channel, 2022-2032
  • Figure 5 : Global Market Value (US$ Mn) by Region, 2022-2032
  • Figure 6 : Global Market Value (US$ Mn) Analysis by Region, 2017-2032
  • Figure 7 : Global Market Value Share (%) and BPS Analysis by Region, 2022-2032
  • Figure 8 : Global Market Y-o-Y Growth (%) Projections by Region, 2022-2032
  • Figure 9 : Global Market Value (US$ Mn) Analysis by Disease Indication, 2017-2032
  • Figure 10 : Global Market Value Share (%) and BPS Analysis by Disease Indication, 2022-2032
  • Figure 11 : Global Market Y-o-Y Growth (%) Projections by Disease Indication, 2022-2032
  • Figure 12 : Global Market Value (US$ Mn) Analysis by Drug Class, 2017-2032
  • Figure 13 : Global Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032
  • Figure 14 : Global Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032
  • Figure 15 : Global Market Value (US$ Mn) Analysis by Route of Administration, 2017-2032
  • Figure 16 : Global Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032
  • Figure 17 : Global Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032
  • Figure 18 : Global Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
  • Figure 19 : Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
  • Figure 20 : Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
  • Figure 21 : Global Market Attractiveness by Disease Indication, 2022-2032
  • Figure 22 : Global Market Attractiveness by Drug Class, 2022-2032
  • Figure 23 : Global Market Attractiveness by Route of Administration, 2022-2032
  • Figure 24 : Global Market Attractiveness by Distribution Channel, 2022-2032
  • Figure 25 : Global Market Attractiveness by Region, 2022-2032
  • Figure 26 : North America Market Value (US$ Mn) by Disease Indication, 2022-2032
  • Figure 27 : North America Market Value (US$ Mn) by Drug Class, 2022-2032
  • Figure 28 : North America Market Value (US$ Mn) by Route of Administration, 2022-2032
  • Figure 29 : North America Market Value (US$ Mn) by Distribution Channel, 2022-2032
  • Figure 30 : North America Market Value (US$ Mn) by Country, 2022-2032
  • Figure 31 : North America Market Value (US$ Mn) Analysis by Country, 2017-2032
  • Figure 32 : North America Market Value Share (%) and BPS Analysis by Country, 2022-2032
  • Figure 33 : North America Market Y-o-Y Growth (%) Projections by Country, 2022-2032
  • Figure 34 : North America Market Value (US$ Mn) Analysis by Disease Indication, 2017-2032
  • Figure 35 : North America Market Value Share (%) and BPS Analysis by Disease Indication, 2022-2032
  • Figure 36 : North America Market Y-o-Y Growth (%) Projections by Disease Indication, 2022-2032
  • Figure 37 : North America Market Value (US$ Mn) Analysis by Drug Class, 2017-2032
  • Figure 38 : North America Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032
  • Figure 39 : North America Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032
  • Figure 40 : North America Market Value (US$ Mn) Analysis by Route of Administration, 2017-2032
  • Figure 41 : North America Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032
  • Figure 42 : North America Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032
  • Figure 43 : North America Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
  • Figure 44 : North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
  • Figure 45 : North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
  • Figure 46 : North America Market Attractiveness by Disease Indication, 2022-2032
  • Figure 47 : North America Market Attractiveness by Drug Class, 2022-2032
  • Figure 48 : North America Market Attractiveness by Route of Administration, 2022-2032
  • Figure 49 : North America Market Attractiveness by Distribution Channel, 2022-2032
  • Figure 50 : North America Market Attractiveness by Country, 2022-2032
  • Figure 51 : Latin America Market Value (US$ Mn) by Disease Indication, 2022-2032
  • Figure 52 : Latin America Market Value (US$ Mn) by Drug Class, 2022-2032
  • Figure 53 : Latin America Market Value (US$ Mn) by Route of Administration, 2022-2032
  • Figure 54 : Latin America Market Value (US$ Mn) by Distribution Channel, 2022-2032
  • Figure 55 : Latin America Market Value (US$ Mn) by Country, 2022-2032
  • Figure 56 : Latin America Market Value (US$ Mn) Analysis by Country, 2017-2032
  • Figure 57 : Latin America Market Value Share (%) and BPS Analysis by Country, 2022-2032
  • Figure 58 : Latin America Market Y-o-Y Growth (%) Projections by Country, 2022-2032
  • Figure 59 : Latin America Market Value (US$ Mn) Analysis by Disease Indication, 2017-2032
  • Figure 60 : Latin America Market Value Share (%) and BPS Analysis by Disease Indication, 2022-2032
  • Figure 61 : Latin America Market Y-o-Y Growth (%) Projections by Disease Indication, 2022-2032
  • Figure 62 : Latin America Market Value (US$ Mn) Analysis by Drug Class, 2017-2032
  • Figure 63 : Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032
  • Figure 64 : Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032
  • Figure 65 : Latin America Market Value (US$ Mn) Analysis by Route of Administration, 2017-2032
  • Figure 66 : Latin America Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032
  • Figure 67 : Latin America Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032
  • Figure 68 : Latin America Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
  • Figure 69 : Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
  • Figure 70 : Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
  • Figure 71 : Latin America Market Attractiveness by Disease Indication, 2022-2032
  • Figure 72 : Latin America Market Attractiveness by Drug Class, 2022-2032
  • Figure 73 : Latin America Market Attractiveness by Route of Administration, 2022-2032
  • Figure 74 : Latin America Market Attractiveness by Distribution Channel, 2022-2032
  • Figure 75 : Latin America Market Attractiveness by Country, 2022-2032
  • Figure 76 : Europe Market Value (US$ Mn) by Disease Indication, 2022-2032
  • Figure 77 : Europe Market Value (US$ Mn) by Drug Class, 2022-2032
  • Figure 78 : Europe Market Value (US$ Mn) by Route of Administration, 2022-2032
  • Figure 79 : Europe Market Value (US$ Mn) by Distribution Channel, 2022-2032
  • Figure 80 : Europe Market Value (US$ Mn) by Country, 2022-2032
  • Figure 81 : Europe Market Value (US$ Mn) Analysis by Country, 2017-2032
  • Figure 82 : Europe Market Value Share (%) and BPS Analysis by Country, 2022-2032
  • Figure 83 : Europe Market Y-o-Y Growth (%) Projections by Country, 2022-2032
  • Figure 84 : Europe Market Value (US$ Mn) Analysis by Disease Indication, 2017-2032
  • Figure 85 : Europe Market Value Share (%) and BPS Analysis by Disease Indication, 2022-2032
  • Figure 86 : Europe Market Y-o-Y Growth (%) Projections by Disease Indication, 2022-2032
  • Figure 87 : Europe Market Value (US$ Mn) Analysis by Drug Class, 2017-2032
  • Figure 88 : Europe Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032
  • Figure 89 : Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032
  • Figure 90 : Europe Market Value (US$ Mn) Analysis by Route of Administration, 2017-2032
  • Figure 91 : Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032
  • Figure 92 : Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032
  • Figure 93 : Europe Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
  • Figure 94 : Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
  • Figure 95 : Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
  • Figure 96 : Europe Market Attractiveness by Disease Indication, 2022-2032
  • Figure 97 : Europe Market Attractiveness by Drug Class, 2022-2032
  • Figure 98 : Europe Market Attractiveness by Route of Administration, 2022-2032
  • Figure 99 : Europe Market Attractiveness by Distribution Channel, 2022-2032
  • Figure 100 : Europe Market Attractiveness by Country, 2022-2032
  • Figure 101 : East Asia Market Value (US$ Mn) by Disease Indication, 2022-2032
  • Figure 102 : East Asia Market Value (US$ Mn) by Drug Class, 2022-2032
  • Figure 103 : East Asia Market Value (US$ Mn) by Route of Administration, 2022-2032
  • Figure 104 : East Asia Market Value (US$ Mn) by Distribution Channel, 2022-2032
  • Figure 105 : East Asia Market Value (US$ Mn) by Country, 2022-2032
  • Figure 106 : East Asia Market Value (US$ Mn) Analysis by Country, 2017-2032
  • Figure 107 : East Asia Market Value Share (%) and BPS Analysis by Country, 2022-2032
  • Figure 108 : East Asia Market Y-o-Y Growth (%) Projections by Country, 2022-2032
  • Figure 109 : East Asia Market Value (US$ Mn) Analysis by Disease Indication, 2017-2032
  • Figure 110 : East Asia Market Value Share (%) and BPS Analysis by Disease Indication, 2022-2032
  • Figure 111 : East Asia Market Y-o-Y Growth (%) Projections by Disease Indication, 2022-2032
  • Figure 112 : East Asia Market Value (US$ Mn) Analysis by Drug Class, 2017-2032
  • Figure 113 : East Asia Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032
  • Figure 114 : East Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032
  • Figure 115 : East Asia Market Value (US$ Mn) Analysis by Route of Administration, 2017-2032
  • Figure 116 : East Asia Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032
  • Figure 117 : East Asia Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032
  • Figure 118 : East Asia Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
  • Figure 119 : East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
  • Figure 120 : East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
  • Figure 121 : East Asia Market Attractiveness by Disease Indication, 2022-2032
  • Figure 122 : East Asia Market Attractiveness by Drug Class, 2022-2032
  • Figure 123 : East Asia Market Attractiveness by Route of Administration, 2022-2032
  • Figure 124 : East Asia Market Attractiveness by Distribution Channel, 2022-2032
  • Figure 125 : East Asia Market Attractiveness by Country, 2022-2032
  • Figure 126 : South Asia & Pacific Market Value (US$ Mn) by Disease Indication, 2022-2032
  • Figure 127 : South Asia & Pacific Market Value (US$ Mn) by Drug Class, 2022-2032
  • Figure 128 : South Asia & Pacific Market Value (US$ Mn) by Route of Administration, 2022-2032
  • Figure 129 : South Asia & Pacific Market Value (US$ Mn) by Distribution Channel, 2022-2032
  • Figure 130 : South Asia & Pacific Market Value (US$ Mn) by Country, 2022-2032
  • Figure 131 : South Asia & Pacific Market Value (US$ Mn) Analysis by Country, 2017-2032
  • Figure 132 : South Asia & Pacific Market Value Share (%) and BPS Analysis by Country, 2022-2032
  • Figure 133 : South Asia & Pacific Market Y-o-Y Growth (%) Projections by Country, 2022-2032
  • Figure 134 : South Asia & Pacific Market Value (US$ Mn) Analysis by Disease Indication, 2017-2032
  • Figure 135 : South Asia & Pacific Market Value Share (%) and BPS Analysis by Disease Indication, 2022-2032
  • Figure 136 : South Asia & Pacific Market Y-o-Y Growth (%) Projections by Disease Indication, 2022-2032
  • Figure 137 : South Asia & Pacific Market Value (US$ Mn) Analysis by Drug Class, 2017-2032
  • Figure 138 : South Asia & Pacific Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032
  • Figure 139 : South Asia & Pacific Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032
  • Figure 140 : South Asia & Pacific Market Value (US$ Mn) Analysis by Route of Administration, 2017-2032
  • Figure 141 : South Asia & Pacific Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032
  • Figure 142 : South Asia & Pacific Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032
  • Figure 143 : South Asia & Pacific Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
  • Figure 144 : South Asia & Pacific Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
  • Figure 145 : South Asia & Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
  • Figure 146 : South Asia & Pacific Market Attractiveness by Disease Indication, 2022-2032
  • Figure 147 : South Asia & Pacific Market Attractiveness by Drug Class, 2022-2032
  • Figure 148 : South Asia & Pacific Market Attractiveness by Route of Administration, 2022-2032
  • Figure 149 : South Asia & Pacific Market Attractiveness by Distribution Channel, 2022-2032
  • Figure 150 : South Asia & Pacific Market Attractiveness by Country, 2022-2032
  • Figure 151 : MEA Market Value (US$ Mn) by Disease Indication, 2022-2032
  • Figure 152 : MEA Market Value (US$ Mn) by Drug Class, 2022-2032
  • Figure 153 : MEA Market Value (US$ Mn) by Route of Administration, 2022-2032
  • Figure 154 : MEA Market Value (US$ Mn) by Distribution Channel, 2022-2032
  • Figure 155 : MEA Market Value (US$ Mn) by Country, 2022-2032
  • Figure 156 : MEA Market Value (US$ Mn) Analysis by Country, 2017-2032
  • Figure 157 : MEA Market Value Share (%) and BPS Analysis by Country, 2022-2032
  • Figure 158 : MEA Market Y-o-Y Growth (%) Projections by Country, 2022-2032
  • Figure 159 : MEA Market Value (US$ Mn) Analysis by Disease Indication, 2017-2032
  • Figure 160 : MEA Market Value Share (%) and BPS Analysis by Disease Indication, 2022-2032
  • Figure 161 : MEA Market Y-o-Y Growth (%) Projections by Disease Indication, 2022-2032
  • Figure 162 : MEA Market Value (US$ Mn) Analysis by Drug Class, 2017-2032
  • Figure 163 : MEA Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032
  • Figure 164 : MEA Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032
  • Figure 165 : MEA Market Value (US$ Mn) Analysis by Route of Administration, 2017-2032
  • Figure 166 : MEA Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032
  • Figure 167 : MEA Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032
  • Figure 168 : MEA Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
  • Figure 169 : MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
  • Figure 170 : MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
  • Figure 171 : MEA Market Attractiveness by Disease Indication, 2022-2032
  • Figure 172 : MEA Market Attractiveness by Drug Class, 2022-2032
  • Figure 173 : MEA Market Attractiveness by Route of Administration, 2022-2032
  • Figure 174 : MEA Market Attractiveness by Distribution Channel, 2022-2032
  • Figure 175 : MEA Market Attractiveness by Country, 2022-2032

Future Market Insights is the premier provider of market intelligence and consulting services, serving client in over 160 countries. FMI is headquartered in London, the global financial capital and has delivery centers in the U.S. and India. FMI's research and consulting services help businesses around the globe navigate the challenges in a rapidly evolving marketplace with confidence and clarity. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. We continuously track emerging trends and events in a broad range of end industries to ensure that our clients prepare for the evolving needs of their customers. FMI's team of over 200 research analysts provides market intelligence at global, regional, and country levels. Our analysts are committed to provide independent insights, relying on our cognitive training modules, which conditions them to look at data objectively and unbiasedly. Others you can use from the file Allen just shared when those will be made live.

Future Markets Insights
Price: $5000

Become a Member

Already a member? Login here.

Have a Question? Ask Us.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
Custom Research

Need a custom data table, graph or complete report? Tell us more.

RELATED REPORTS